BIOM辅助经玻璃体葡萄膜黑色素瘤活检:技术、适应证与结局
该回顾性病例系列描述了27例葡萄膜黑色素瘤患者采用BIOM辅助经玻璃体活检的技术,并评估其安全性和用于预后基因表达谱检测的取材有效性。并发症多为轻微、短暂且自限,所有活检均获得足够组织用于基因表达谱分析;与经巩膜活检组比较,经玻璃体活检更常用于小肿瘤和后部肿瘤。
要点
- 经玻璃体活检适用于小肿瘤、后部肿瘤或经巩膜入路有肿瘤穿孔风险的小前部肿瘤。
- 术中常见活检部位血凝块或少量渗血(74.1%),其次为局限性视网膜下出血(29.6%)。
- 视网膜下出血几乎均发生于既存视网膜下液腔(P=0.0093),但视网膜下液存在不影响活检方式选择。
核心结论
- 该经玻璃体活检技术可用于小肿瘤、后部肿瘤或经巩膜入路有肿瘤穿孔风险的小前部肿瘤,并发症轻微、短暂且自限,所有病例均获得足够组织用于分子预后检测。
研究设计与样本
- 研究为手术技术描述加回顾性病例系列,纳入2013至2016年接受所述经玻璃体活检的27例葡萄膜黑色素瘤患者,并以同期接受经巩膜活检的20例患者(21个葡萄膜黑色素瘤)作为比较组。
主要发现
- 27例患者年龄27.2至88.6岁(平均64.8岁),诊断时肿瘤为15个小、10个中等、2个大,多数(n=17)位于赤道后。
- 术中并发症包括活检部位血凝块或少量渗血20例(74.1%)、局限性视网膜下出血8例(29.6%)、少量玻璃体出血4例(14.8%)、短暂局限性脉络膜脱离1例(3.6%)。
- 视网膜下出血发生时几乎均进入既存视网膜下液腔(P=0.0093),但视网膜下液的存在与是否进行任何活检(P=0.36)或 specifically 经玻璃体活检(P=1.00)的决定无关。
- 截至3个月,视网膜下和/或玻璃体出血基本全部消退;平均随访41.7个月(范围20-62.1个月)内无医源性视网膜脱离或眼外肿瘤播散病例。
- 与同期经巩膜活检患者相比,经玻璃体活检更常见于小肿瘤(n=15;P<0.0001)和后部肿瘤(n=17;P<0.0001)。
关键数值与推荐
- 所有经玻璃体活检均获得足够组织用于基因表达谱分析。
- 视网膜下液存在可视为相对禁忌证,因其可能导致液腔内视网膜下出血,但并未阻止对获益患者使用该经玻璃体技术。
临床怎么用
- 对于小肿瘤、后部肿瘤或经巩膜入路有肿瘤穿孔风险的小前部肿瘤,可考虑采用BIOM辅助经玻璃体活检获取组织用于预后基因表达谱检测。
- 术前存在视网膜下液时,应告知视网膜下出血风险增加,但该情况并非经玻璃体活检的绝对禁忌。
局限性
- 研究为回顾性病例系列,样本量较小(经玻璃体活检27例),随访时间有限,比较组为非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Controversy exists regarding the best method for biopsy of uveal melanoma. We describe our transvitreal technique and evaluate the safety of this technique as well as the efficacy for obtaining sample for prognostic genetic profiling. METHODS: Description of surgical technique and retrospective case series. Medical records for uveal melanoma patients who underwent transvitreal biopsy using our described technique were analyzed for tumor size, location, primary treatment, method of biopsy, and any complications thereof. Characteristics of tumors that underwent transvitreal biopsy were noted including tumor size, location, or presence of subretinal fluid, to see whether these affected surgeon preference for biopsy modality. A cohort of contemporaneous uveal melanoma patients who underwent biopsy through a transscleral technique served as a comparator group for these patient, tumor, and complication factors. RESULTS: A total of 27 patients aged 27.2 to 88.6 years (mean 64.8) underwent transvitreal biopsy using our described technique between 2013 and 2016. There were 15 small, 10 medium, and 2 large tumors at diagnosis with the majority (n = 17) posterior to the equator. Intraoperative complications included a clot or small trickle of blood at the biopsy site in 20 (74.1%) of patients, small localized subretinal hemorrhage in 8 (29.6%), small vitreous hemorrhage in 4 (14.8%), and small transient choroidal detachments in 1 patient (3.6%). When subretinal hemorrhage occurred, it was almost always into a pre-existing pocket of subretinal fluid ( P = 0.0093). However, the presence of subretinal fluid was not associated with the decision to proceed with any biopsy ( P = 0.36) or transvitreal biopsy specifically ( P = 1.00). By 3 months, subretinal and/or vitreous hemorrhage resolved in essentially all cases. There were no cases of iatrogenic retinal detachment or extraocular tumor spread over a mean follow-up of 41.7 (range: 20-62.1) months. Adequate tissue for gene expression profiling was obtained from each biopsy. The comparator group of patients undergoing transscleral biopsy including 21 uveal melanomas in 20 patients (one eye had two melanomas). Transvitreal biopsies were more common in patients with small (n = 15; P < 0.0001), posterior (n = 17; P < 0.0001) tumors, compared with patients who underwent transscleral biopsy during the same period. CONCLUSION: This technique can be used for small or posterior tumors or for small anterior tumors where a transscleral approach would risk tumor perforation. Complications were minor, transient, and self-limited. Biopsy yields for molecular prognosis were adequate in all cases. The presence of subretinal fluid may be considered a relative contraindication because it may lead to subretinal hemorrhage in the fluid pocket but did not dissuade us from using this transvitreal technique for patients who would benefit from it.
引用
- Snyder LL, Daniels AB. Surgical Technique, Indications, and Outcomes of BIOM-Assisted Transvitreal Biopsy for Uveal Melanoma. Retina. 2019. PMID: 31815876. doi:10.1097/IAE.0000000000002677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。